Journal Mobile Options
Table of Contents
Vol. 229, No. 4, 2013
Issue release date: May 2013
Ophthalmologica 2013;229:219-226
(DOI:10.1159/000350496)

Citicoline Oral Solution in Glaucoma: Is There a Role in Slowing Disease Progression?

Ottobelli L. · Manni G.L. · Centofanti M. · Iester M. · Allevena F. · Rossetti L.
aEye Clinic, San Paolo Hospital, University of Milan, Milan, bDipartimento di Scienze Cliniche e Medicina Traslazionale, University of Rome Tor Vegata, and cFondazione G.B. Bietti per l'Oftalmologia, IRCCS, Rome, and dLaboratorio Clinico Anatomo-Funzionale per la Diagnosi e il Trattamento del Glaucoma e delle Malattie Neurooftalmologiche, Clinica Oculistica, DINOGMI, University of Genoa, Genoa, Italy

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Purpose: To assess the effect of citicoline on visual field rates of progression in patients with progressing glaucoma. Patients and Methods: Forty-one patients with a diagnosis of progressing glaucoma received citicoline in oral solution for 2 years. Included were patients with a disease progression of at least -1 dB/year (at MD, mean deviation) for at least 3 years before entering the study despite controlled intraocular pressure (IOP). Patients were followed with 4 visual field examinations per year for 2 years. Results: At baseline, the mean rate of progression was -1.1 (±0.7) dB/year despite the fact that the IOP had been below 18 mm Hg for at least 3 years. At study inclusion, the mean IOP was 15.5 (±2.6) mm Hg and the mean MD was -9.2 (±6.7) dB in the worst eye. Starting from the first cycle of treatment with citicoline, the mean rate of progression significantly changed to -0.15 (±0.3) dB/year at the end of the study (p = 0.01). Conclusions: This study seems to indicate that supplementation with citicoline might significantly slow down glaucomatous rates of progression.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Magnitude and causes of visual impairment. Fact sheet No 282, November 2004. http//www.who.int/mediacentre/factsheets/fs282/en/ (accessed February 8, 2006).
  2. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M: Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-1279.

    External Resources

  3. The Advanced Glaucoma Intervention Study (AGIS). 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000;130:429-440.
  4. Maier PC, Funk J, Schwarzer G, Antes G, Falck-Ytter YT: Treatment of ocular hypertension and glaucoma: meta-analysis of randomised controlled trials. BMJ 2005;331:134.
  5. Foganolo P, Rossetti L: Medical treatment of glaucoma: present and future. Expert Opin Investig Drugs 2011;20:947-959.
  6. Medeiros FA, Alencar LM, Zangwill LM, Sample PA, Weinreb RN: The relationship between intraocular pressure and progressive retinal nerve fiber layer loss in glaucoma. Ophthalmology 2009;116:1125-1133.
  7. Medeiros FA, Alencar LM, Sample PA, Zangwill LM, Susanna R Jr, Weinreb RN: The relationship between intraocular pressure reduction and rates of progressive visual field loss in eyes with optic disc hemorrhage. Ophthalmology 2010;117:2061-2066.
  8. De Moraes CG, Demirel S, Gardiner SK, Liebmann JM, Cioffi GA, Ritch R, Gordon MO, Kass MA: Effect of treatment on the rate of visual field change in the ocular hypertension treatment study observation group. Invest Ophthalmol Vis Sci 2012;53:1704-1709.
  9. Chauhan BC, Mikelberg FS, Artes PH, Balazsi AG, LeBlanc RP, Lesk MR, Nicolela MT, Trope GE: Canadian Glaucoma Study. 3. Impact of risk factors and intraocular pressure reduction on the rates of visual field change. Arch Ophthalmol 2010;128:1249-1255.
  10. Sommer A: Intraocular pressure and glaucoma. Am J Ophthalmol 1989;107:186-188.

    External Resources

  11. Baltmr A, Duggan J, Nizari S, Salt TE, Cordeiro MF: Neuroprotection in glaucoma - is there a future role? Exp Eye Res 2010;91:554-566.
  12. Cheung W, Guo L, Cordeiro MF: Neuroprotection in glaucoma: drug-based approaches. Optom Vis Sci 2008;85:406-416.

    External Resources

  13. Osborne NN: Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol 2009;87:450-454.
  14. Secades JJ, Lorenzo JL: Citicoline: pharmacological and clinical review, 2006 update. Methods Find Exp Clin Pharmacol 2006;28 suppl B:1-56.

    External Resources

  15. Hazama T, Hasegawa T, Ueda S, Sakuma A: Evaluation of the effect of CDP-choline on poststroke hemiplegia employing a double-blind controlled trial. Assessed by a new rating scale for recovery in hemiplegia. Int J Neurosci 1980;11:211-225.
  16. Spiers PA, Myers D, Hochanadel GS, Lieberman HR, Wurtman RJ: Citicoline improves verbal memory in aging. Arch Neurol 1996;53:441-448.
  17. Alvarez XA, Laredo M, Corzo D, Fernández-Novoa L, Mouzo R, Perea JE, Daniele D, Cacabelos R: Citicoline improves memory performance in elderly subjects. Methods Find Exp Clin Pharmacol 1997;19:201-210.

    External Resources

  18. Shimamoto K, Hirano T, Aramaki Y: Therapeutic mechanism of cytidine diphosphate choline (CDP-choline) in parkinsonism. J Takeda Res Lab 1975;34:440-448.
  19. Ruggieri S, Zamponi A, Casacchia M, Agnoli A: Effetti terapeutici della citicolina (citidin-difosfo-colina) nella sindrome parkinsoniana. Clin Ter 1976;78:515-525.

    External Resources

  20. Agnoli A, Ruggieri S, Denaro A, Bruno G: New strategies in the management of Parkinson's disease: a biological approach using a phospholipid precursor (CDP-choline). Neuropsychobiology 1982;8:289-296.
  21. Fresina M, Dickmann A, Salerni A, De Gregorio F, Campos EC: Effect of oral CDP-choline on visual function in young amblyopic patients. Graefes Arch Clin Exp Ophthalmol 2008;246:143-150.
  22. Porciatti V, Schiavi C, Benedetti P, Baldi A, Campos EC: Cytidine-5′-diphosphocholine improves visual acuity, contrast sensitivity and visually evoked potentials of amblyopic subjects. Curr Eye Res 1998;17:141-148.
  23. Campos EC, Bolzani R, Schiavi C, Baldi A, Porciatti V: Cytidin-5′-diphosphocholine enhances the effect of part-time occlusion in amblyopia. Doc Ophthalmol 1996;93:247-263.
  24. Campos EC, Schiavi C, Benedetti P, Bolzani R, Porciatti V: Effect of citicoline on visual acuity in amblyopia: preliminary results. Graefes Arch Clin Exp Ophthalmol 1995;233:307-312.
  25. Parisi V, Coppola G, Ziccardi L, Gallinaro G, Falsini B: Cytidine-5′′-diphosphocholine (citicoline): a pilot study in patients with non-arteritic ischaemic optic neuropathy. Eur J Neurol 2008;15:465-474.
  26. Parisi V, Manni G, Colacino G, Bucci GM: Cytidine-5′-diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology 1999;106:1126-1134.
  27. Parisi V: Electrophysiological assessment of glaucomatous visual dysfunction during treatment with cytidine-5′-diphosphocholine (citicoline): a study of 8 years of follow-up. Doc Ophthalmol 2005;110:91-102.
  28. Virno M, Pecori-Giraldi J, Liguori A, De Gregorio F: The protective effect of citicoline on the progression of the perimetric defects in glaucomatous patients (perimetric study with a 10-year follow-up). Acta Ophthalmol Scand Suppl 2000;232:56-57.
  29. Rejdak R, Toczolowski J, Kurkowski J, Kaminski ML, Rejdak K, Stelmasiak Z, Grieb P: Oral citicoline treatment improves visual pathway function in glaucoma. Med Sci Monit 2003;9:PI24-PI28.

    External Resources

  30. Grieb P, Rejdak R: Pharmacodynamics of citicoline relevant to the treatment of glaucoma. J Neurosci Res 2002;67:143-148.
  31. Pecori-Giraldi J, Virno M, Covelli G, Grechi G, De Gregorio F: Therapeutic value of citicoline in the treatment of glaucoma (computerized and automated perimetric investigation). Int Ophthalmol 1989;13:109-112.
  32. Roda A, Fini A, Grigolo B: Routes of administration and serum levels of (methyl C14) citicoline. Curr Ther Res Clin Exp 1983;4:1050-1053.
  33. Rossetti L, Goni F, Denis P, Bengtsson B, Martinez A, Heijl A: Focusing on glaucoma progression and the clinical importance of progression rate measurement: a review. Eye 2010;24:S1-S7.
  34. Secades JJ, Frontera G: CDP-choline: pharmacological and clinical review. Methods Find Exp Clin Pharmacol 1995;17(suppl B):1-54.

    External Resources

  35. Weiss GB: Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sci 1995;56:637-660.
  36. Dávalos A, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Ferro J, Martínez-Vila E, Serena J, Segura T, Cruz VT, Masjuan J, Cobo E, Secades JJ, International Citicoline Trial on Acute Stroke (ICTUS) trial investigators: Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 2012;380:349-357.
  37. Cacabelos R, Caamaño J, Gómez MJ, Fernández-Novoa L, Franco-Maside A, Alvarez XA: Therapeutic effects of CDP-choline in Alzheimer's disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors. Ann NY Acad Sci 1996 17;777:399-403.
  38. Parisi V, Coppola G, Centofanti M, Oddone F, Angrisani AM, Ziccardi L, Ricci B, Quaranta L, Manni G: Evidence of the neuroprotective role of citicoline in glaucoma patients. Prog Brain Res 2008;173:541-554.
  39. Quigley HA: Clinical trials for glaucoma neuroprotection are not impossible. Curr Opin Ophthalmol 2012;23:144-154.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50